About sellas life sciences group - SLS
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
SLS At a Glance
SELLAS Life Sciences Group, Inc.
Times Square Tower
New York, New York 10036
| Phone | 1-646-200-5278 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -26,863,000.00 | |
| Sector | Health Technology | Employees | 13 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
SLS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 8.144 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -12.033 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.003 |
SLS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,066,384.615 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
SLS Liquidity
| Current Ratio | 10.718 |
| Quick Ratio | 10.718 |
| Cash Ratio | 10.246 |
SLS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -54.835 |
| Return on Equity | -66.877 |
| Return on Total Capital | -37.376 |
| Return on Invested Capital | -66.124 |
SLS Capital Structure
| Total Debt to Total Equity | 1.412 |
| Total Debt to Total Capital | 1.393 |
| Total Debt to Total Assets | 1.278 |
| Long-Term Debt to Equity | 0.645 |
| Long-Term Debt to Total Capital | 0.636 |